LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

LLY

795.52

-1.93%↓

JNJ

153.03

-1.23%↓

ABBV

186.25

-2.5%↓

NVO

74.55

-3.33%↓

UNH

307.75

-0.01%↓

Compugen Ltd

Отворен

1.64 0.61

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.55

Максимум

1.66

Ключови измерители

By Trading Economics

Приходи

-1.1M

-7.2M

Продажби

813K

2.3M

P/E

Средно за сектора

60.333

51.748

EPS

-0.08

Марж на печалбата

-314.405

Служители

74

EBITDA

-12M

-7.5M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+326.83% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-527M

159M

Предишно отваряне

1.03

Предишно затваряне

1.64

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Compugen Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.06.2025 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

KKR to Acquire Australian Power Provider Zenith Energy

16.06.2025 г., 21:55 ч. UTC

Значими двигатели на пазара

Geospace Technologies Shares Up on Petrobras Pact

16.06.2025 г., 17:04 ч. UTC

Значими двигатели на пазара

Roku Shares Climb on Advertising Deal with Amazon

16.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16.06.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16.06.2025 г., 23:10 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16.06.2025 г., 23:02 ч. UTC

Пазарно говорене

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16.06.2025 г., 22:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16.06.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16.06.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16.06.2025 г., 21:56 ч. UTC

Печалби

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16.06.2025 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

16.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.06.2025 г., 20:49 ч. UTC

Пазарно говорене

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16.06.2025 г., 20:13 ч. UTC

Пазарно говорене

Natural Gas Gains on Warmer Outlook -- Market Talk

16.06.2025 г., 19:58 ч. UTC

Придобивния, сливания и поглъщания

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16.06.2025 г., 19:13 ч. UTC

Пазарно говорене

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16.06.2025 г., 19:09 ч. UTC

Пазарно говорене

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16.06.2025 г., 18:43 ч. UTC

Пазарно говорене

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16.06.2025 г., 18:36 ч. UTC

Пазарно говорене

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Shopify Appears More Resilient Than Feared -- Market Talk

16.06.2025 г., 18:22 ч. UTC

Пазарно говорене

Citi Forecasts Downturn in Gold Futures -- Market Talk

16.06.2025 г., 16:42 ч. UTC

Пазарно говорене

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16.06.2025 г., 16:37 ч. UTC

Пазарно говорене

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Compugen Ltd Прогноза

Ценова цел

By TipRanks

326.83% нагоре

12-месечна прогноза

Среден 7 USD  326.83%

Висок 10 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Compugen Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

1.25 / 1.48Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.